Glucose-dependent insulinotropic polypeptide signaling in pancreatic β-cells and adipocytes

Journal of Diabetes Investigation

Volumn 3, Issue 2, 2012, Pages 96-106

  McIntosh, Christopher H S ^a   Widenmaier, Scott ^a,b   Kim, Su Jin ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Apoptosis; Glucose dependent insulinotropic polypeptide; Incretin

Indexed keywords

APOPTOSIS SIGNAL REGULATING KINASE 1; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; EXCHANGE PROTEIN DIRECTLY ACTIVATED BY CYCLIC ADENOSINE MONOPHOSPHATE 2; G PROTEIN COUPLED RECEPTOR; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR; INCRETIN; INSULIN; LIPOPROTEIN LIPASE; MESSENGER RNA; PROTEIN BCL 2; PROTEIN KINASE B; RESISTIN; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL;

ADIPOCYTE; ADIPOGENESIS; APOPTOSIS; BROWN ADIPOSE TISSUE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SECRETION; CELL SURVIVAL; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR GENE; HUMAN; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INTRACELLULAR SIGNALING; MITOCHONDRIAL MEMBRANE POTENTIAL; MOLECULAR DYNAMICS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PROCESSING; REGULATOR GENE; REVIEW;

EID: 84859124238     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2012.00196.x     Document Type: Review

References (123)

1. Brubaker PL. The glucagon-like peptides: pleiotropic regulators of nutrient homeostasis. Ann N Y Acad Sci 2006; 1070: 10-26.
2. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type2 diabetes. Lancet 2006; 368: 1696-1705.
3. McIntosh CHS, Widenmaier S, Kim S-J. Glucose-dependent insulinotropic polypeptide (Gastric Inhibitory Polypeptide; GIP). Vitam Horm 2009; 80: 409-471.
4. McIntosh CHS, Widenmaier S, Kim S-J. Pleiotropic actions of the incretin hormones. Vitam Horm 2010; 84: 21-79.
5. Holst JJ, Vilsbøll T, Deacon CF. The incretin system and its role in type2 diabetes mellitus. Mol Cell Endocrinol 2009; 297: 127-136.
6. McIntosh CHS. Dipeptidyl peptidase IV inhibitors and diabetes therapy. Front Biosci 2008; 13: 1753-1773.
7. Irwin D. Molecular evolution of mammalian incretin hormone genes. Regul Pept 2009; 155: 121-130.
8. Jia X, Brown JC, Ma P, et al. Effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-I-(7-36) on insulin secretion. Am J Physiol 1995; 268: E645-E651.
9. Pederson RA, Brown JC. The insulinotropic action of gastric inhibitory polypeptide in the perfused isolated rat pancreas. Endocrinology 1976; 99: 780-785.
10. Vilsbøll T, Krarup T, Madsbad S, et al. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept 2003; 114: 115-121.
11. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3: 153-165.
12. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131-2157.
13. Doyle ME, Egan JM. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 2007; 113: 546-593.
14. Yu Z, Jin T. New insights into the role of cAMP in the production and function of the incretin hormone glucagon-like peptide-1 (GLP-1). Cell Signal 2010; 22: 1-8.
15. Leech CA, Chepurny OG, Holz GG. Epac2-dependent rap1 activation and the control of islet insulin secretion by glucagon-like peptide-1. Vitam Horm 2010; 84: 279-302.
16. Ashcroft F, Rorsman P. Molecular defects in insulin secretion in type-2 diabetes. Rev Endocr Metab Disord 2004; 4: 135-142.
17. Hinke SA, Hellemans K, Schuit FC. Plasticity of the beta cell insulin secretory competence: preparing the pancreatic beta cell for the next meal. J Physiol (Lond) 2004; 558: 369-380.
18. Hiriart M, Aguilar-Bryan L. Channel regulation of glucose sensing in the pancreatic beta-cell. Am J Physiol Endocrinol Metab 2008; 295: 1298-1306.
19. + channels in pancreatic beta cells: role, regulation and potential as therapeutic targets. Diabetologia 2003; 46: 1046-1062.
20. Kashima Y, Miki T, Shibasaki T, et al. Critical role of cAMP-GEFII--Rim2 complex in incretin-potentiated insulin secretion. J Biol Chem 2001; 276: 46046-46053.
21. Seino S, Shibasaki T. PKA-dependent and PKA-independent pathways for cAMP-regulated exocytosis. Physiol Rev 2005; 85: 1303-1342.
22. Hinke SA, Pauly RP, Ehses J, et al. Role of glucose in chronic desensitization of isolated rat islets and mouse insulinoma (betaTC-3) cells to glucose-dependent insulinotropic polypeptide. J Endocrinol 2000; 165: 281-291.
23. Ehses JA, Pelech SL, Pederson RA, et al. Glucose-dependent insulinotropic polypeptide activates the Raf-Mek1/2-ERK1/2 module via a cyclic AMP/cAMP-dependent protein kinase/Rap1-mediated pathway. J Biol Chem 2002; 277: 37088-37097.
24. 2+ and cAMP oscillations in pancreatic beta-cells: a role for glucose metabolism and GLP-1 receptors? Am J Physiol Cell Physiol 2008; 294: C4-C6.
25. 2+ regulation of adenylyl cyclase in cAMP microdomains. Physiol Rev 2007; 87: 965-1010.
26. 2+ and G protein-coupled receptors in the pancreatic beta-cell: a computational approach. Am J Physiol Cell Physiol 2007; 294: C1924-C1933.
27. Holz GG. New insights concerning the glucose-dependent insulin secretagogue action of glucagon-like peptide-1 in pancreatic beta-cells. Horm Metab Res 2004; 36: 787-794.
28. Seino S, Takahashi H, Fujimoto W, et al. Roles of cAMP signaling in insulin granule exocytosis. Diabetes Obes Metab 2009; 11(Suppl 4): 180-188.
29. Holz GG. Epac: A new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic beta-cell. Diabetes 2004; 53: 5-13.
30. Holz GG, Kang G, Harbeck M, et al. Cell physiology of cAMP sensor Epac. J Physiol (Lond) 2006; 577: 5-15.
31. Chepurny OG, Kelley GG, Dzhura I, et al. PKA-dependent potentiation of glucose-stimulated insulin secretion by Epac activator 8-pCPT-2′-O-Me-cAMP-AM in human islets of Langerhans. Am J Physiol Endocrinol Metab 2010; 298: E622-E633.
32. Seino S, Shibasaki T, Minami K. Dynamics of insulin secretion and the clinical implications for obesity and diabetes. J Clin Invest 2011; 121: 2118-2125.
33. Gromada J, Bokvist K, Ding WG, et al. Glucagon-like peptide 1 (7-36) amide stimulates exocytosis in human pancreatic beta-cells by both proximal and distal regulatory steps in stimulus-secretion coupling. Diabetes 1998; 47: 57-65.
34. Light PE, Manning Fox JE, Riedel MJ, et al. Glucagon-like peptide-1 inhibits pancreatic ATP-sensitive potassium channels via a protein kinase A- and ADP-dependent mechanism. Mol Endocrinol 2002; 16: 2135-2144.
35. Kasai H, Hatakeyama H, Ohno M, et al. Exocytosis in islet beta-cells. Adv Exp Med Biol 2010; 654: 305-338.
36. Niimura M, Miki T, Shibasaki T, et al. Critical role of the N-terminal cyclic AMP-binding domain of Epac2 in its subcellular localization and function. J Cell Physiol 2009; 219: 652-658.
37. Kang G, Chepurny OG, Malester B, et al. cAMP sensor Epac as a determinant of ATP-sensitive potassium channel activity in human pancreatic beta cells and rat INS-1 cells. J Physiol (Lond) 2006; 573: 595-609.
38. 2+ channel in insulin granule exocytosis. J Biol Chem 2004; 279: 7956-7961.
39. Shibasaki T, Takahashi H, Miki T, et al. Essential role of Epac2/Rap1 signaling in regulation of insulin granule dynamics by cAMP. Proc Natl Acad Sci USA 2007; 104: 19333-19338.
40. Dzhura I, Chepurny OG, Leech CA, et al. Phospholipase C-epsilon links Epac2 activation to the potentiation of glucose-stimulated insulin secretion from mouse islets of Langerhans. Islets 2011; 3: 121-128.
41. Baukrowitz T, Schulte U, Oliver D, et al. PIP2 and PIP as determinants for ATP inhibition of KATP channels. Science 1998; 282: 1141-1144.
42. Shyng S-L, Nichols C. Membrane phospholipid control of nucleotide sensitivity of KATP channels. Science 1998; 282: 1138-1141.
43. Lu M, Wheeler MB, Leng XH, et al. Stimulation of insulin secretion and insulin gene expression by gastric inhibitory polypeptide. Trans Assoc Am Phys 1993; 106: 42-53.
44. Wheeler MB, Gelling RW, McIntosh CHS, et al. Functional expression of the rat pancreatic islet glucose-dependent insulinotropic polypeptide receptor: ligand binding and intracellular signaling properties. Endocrinology 1995; 136: 4629-4639.
45. Miki T, Minami K, Shinozaki H, et al. Distinct effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 on insulin secretion and gut motility. Diabetes 2005; 54: 1056-1063.
46. Gloerich M, Bos JL. Epac: defining a new mechanism for cAMP action. Annu Rev Pharmacol Toxicol 2010; 50: 355-375.
47. Ehses JA, Lee SS, Pederson RA, et al. A new pathway for glucose-dependent insulinotropic polypeptide (GIP) receptor signaling: evidence for the involvement of phospholipase A2 in GIP-stimulated insulin secretion. J Biol Chem 2001; 276: 23667-23673.
48. MacDonald PE, El-Kholy W, Riedel MJ, et al. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes 2002; 51(Suppl 3): S434-S442.
49. Kim S-J, Choi WS, Han JSM, et al. A novel mechanism for the suppression of a voltage-gated potassium channel by glucose-dependent insulinotropic polypeptide: protein kinase A-dependent endocytosis. J Biol Chem 2005; 280: 28692-28700.
50. + currents in beta-cells: a possible glucose-dependent insulinotropic mechanism. Diabetes 2002; 51(Suppl 3): S443-S447.
51. Kim S-J, Widenmaier SB, Choi WS, et al. Pancreatic β-cell prosurvival effects of the incretin hormones involve post-translational modification of Kv2.1 delayed rectifier channels. Cell Death Differ 2012; 19: 333-344.
52. Jacobson DA, Weber CR, Bao S, et al. Modulation of the pancreatic islet β-cell-delayed rectifier potassium channel Kv2.1 by the polyunsaturated fatty acid arachidonate. J Biol Chem 2007; 282: 7442-7449.
53. Ding WG, Gromada J. Protein kinase A-dependent stimulation of exocytosis in mouse pancreatic beta-cells by glucose-dependent insulinotropic polypeptide. Diabetes 1997; 46: 615-621.
54. Eliasson L, Ma X, Renstrom E, et al. SUR1 regulates PKA-independent cAMP-induced granule priming in mouse pancreatic B-cells. J Gen Physiol 2003; 121: 181-197.
55. Yasuda T, Shibasaki T, Minami K, et al. Rim2alpha determines docking and priming states in insulin granule exocytosis. Cell Metab 2010; 12: 117-129.
56. Song W-J, Seshadri M, Ashraf U, et al. Snapin mediates incretin action and augments glucose-dependent insulin secretion. Cell Metab 2011; 13: 308-319.
57. Widenmaier SB, Sampaio AV, Underhill TM, et al. Noncanonical activation of Akt/protein kinase B in β-cells by the incretin hormone glucose-dependent insulinotropic polypeptide. J Biol Chem 2009; 284: 10764-10773.
58. Mandrup-Poulsen T. Apoptotic signal transduction pathways in diabetes. Biochem Pharmacol 2003; 66: 1433-1440.
59. Rhodes CJ. Type2 diabetes-a matter of beta-cell life and death? Science 2005; 307: 380-384.
60. Perl S, Kushner JA, Buchholz BA, et al. Significant human beta-cell turnover is limited to the first three decades of life as determined by in vivo thymidine analog incorporation and radiocarbon dating. J Clin Endocrinol Metab 2010; 95: E234-E249.
61. Cnop M, Igoillo-Esteve M, Hughes SJ, et al. Longevity of human islet alpha- and beta-cells. Diabetes Obes Metab 2011; 13(Suppl 1): 39-46.
62. Li Y, Hansotia T, Yusta B, et al. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 2003; 278: 471-478.
63. Wang Q, Brubaker PL. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8week-old db/db mice. Diabetologia 2002; 45: 1263-1273.
64. Farilla L, Hui H, Bertolotto C, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002; 143: 4397-4408.
65. Kim S-J, Winter K, Nian C, et al. Glucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and down-regulation of bax expression. J Biol Chem 2005; 280: 22297-22307.
66. Maida A, Hansotia T, Longuet C, et al. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice. Gastroenterology 2009; 137: 2146-2157.
67. Widenmaier SB, Kim S-J, Yang GK, et al. A GIP receptor agonist exhibits beta-cell anti-apoptotic actions in rat models of diabetes resulting in improved beta-cell function and glycemic control. PLoS One 2010; 5: e9590.
68. Widenmaier SB, Ao Z, Kim S-J, et al. Suppression of p38 MAPK and JNK via Akt-mediated inhibition of apoptosis signal-regulating kinase 1 constitutes a core component of the beta-cell pro-survival effects of glucose-dependent insulinotropic polypeptide. J Biol Chem 2009; 284: 30372-30382.
69. Ehses JA, Casilla VR, Doty T, et al. Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. Endocrinology 2003; 144: 4433-4445.
70. Kim S-J, Nian C, Widenmaier S, et al. Glucose-dependent insulinotropic polypeptide-mediated up-regulation of beta-cell antiapoptotic Bcl-2 gene expression is coordinated by cyclic AMP (cAMP) response element binding protein (CREB) and cAMP-responsive CREB coactivator 2. Mol Cell Biol 2008; 28: 1644-1656.
71. Hui H, Nourparvar A, Zhao X, et al. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5′-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 2003; 144: 1444-1455.
72. Jhala US, Canettieri G, Screaton RA, et al. cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2. Genes Dev 2003; 17: 1575-1580.
73. Van de Velde S, Hogan MF, Montminy M. mTOR links incretin signaling to HIF induction in pancreatic beta cells. Proc Natl Acad Sci USA 2011; 108: 16876-16882.
74. Trümper K, Trümper A, Trusheim H, et al. Integrative mitogenic role of protein kinase B/Akt in beta-cells. Ann N Y Acad Sci 2000; 921: 242-250.
75. Trümper A, Trümper K, Trusheim H, et al. Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Mol Endocrinol 2001; 15: 1559-1570.
76. Tobiume T, Saitoh M, Ichijo H. Activation of Apoptosis Signal-Regulating Kinase 1 by the stress-induced activating phosphorylation of pre-formed oligomer. J Cell Physiol 2002; 191: 95-104.
77. Takeda K, Noguchi T, Naguro I, et al. Apoptosis signal-regulating kinase 1 in stress and immune response. Annu Rev Pharmacol Toxicol 2008; 48: 199-225.
78. Kim S-J, Nian C, McIntosh CHS. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 modulate beta-cell chromatin structure. J Biol Chem 2009; 284: 12896-12904.
79. Cunha DA, Ladriere L, Ortis F, et al. Glucagon-like peptide-1 agonists protect pancreatic beta-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB. Diabetes 2009; 58: 2851-2862.
80. Yusta B, Baggio LL, Estall JL, et al. GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress. Cell Metab 2006; 4: 391-406.
81. + currents. Neurosci Lett 2005; 387: 136-140.
82. Lardinois CK, Starich GH, Mazzaferri EL. The postprandial response of gastric inhibitory polypeptide to various dietary fats in man. J Am Coll Nutr 1988; 7: 241-247.
83. Pederson RA. Gastric inhibitory polypeptide. In: Walsh JH, Dockray GJ (eds). Gut Peptides: Biochemistry and Physiology. Raven Press, New York, 1994; 217-259.
84. Wasada T, McCorkle K, Harris V, et al. Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs. J Clin Invest 1981; 68: 1106-1107.
85. Ebert R, Nauck M, Creutzfeldt W. Effect of exogenous or endogenous gastric inhibitory polypeptide (GIP) on plasma triglyceride responses in rats. Horm Metab Res 1991; 23: 517-521.
86. Jorde R, Pettersen JE, Burhol PG. Lack of effect of exogenous or endogenous gastric inhibitory polypeptide on the elimination rate of Intralipid in man. Acta Med Scand 1984; 216: 19-23.
87. Miyawaki K, Yamada Y, Ban N, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 2002; 8: 738-742.
88. Irwin N, Flatt PR. Therapeutic potential for GIP receptor agonists and antagonists. Baillieres Best Pract Res Clin Endocrinol Metab 2009; 23: 499-512.
89. Fulurija A, Lutz TA, Sladko K, et al. Vaccination against GIP for the treatment of obesity. PLoS One 2008; 3: e3163.
90. Althage MC, Ford EL, Wang S, et al. Targeted ablation of glucose-dependent insulinotropic polypeptide-producing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet. J Biol Chem 2008; 283: 18365-18376.
91. Oben J, Morgan L, Fletcher J, et al. Effect of the entero-pancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1(7-36) amide, on fatty acid synthesis in explants of rat adipose tissue. J Endocrinol 1991; 130: 267-272.
92. Hauner H, Glatting G, Kaminska D, et al. Effects of gastric inhibitory polypeptide on glucose and lipid metabolism of isolated rat adipocytes. Ann Nutr Metab 1988; 32: 282-288.
93. Beck B, Max JP. Direct metabolic effects of gastric inhibitory polypeptide (GIP): dissociation at physiological levels of effects on insulin-stimulated fatty acid and glucose incorporation in rat adipose tissue. Diabetologia 1986; 29: 68.
94. Eckel RH, Fujimoto WY, Brunzell JD. Gastric inhibitory polypeptide enhanced lipoprotein lipase activity in cultured preadipocytes. Diabetes 1979; 28: 1141-1142.
95. Kim S-J, Nian C, McIntosh CHS. Activation of lipoprotein lipase by glucose-dependent insulinotropic polypeptide in adipocytes. A role for a protein kinase B, LKB1, and AMP-activated protein kinase cascade. J Biol Chem 2007; 282: 8557-8567.
96. Kim S-J, Nian C, McIntosh CHS. Resistin is a key mediator of glucose-dependent insulinotropic polypeptide (GIP) stimulation of lipoprotein lipase (LPL) activity in adipocytes. J Biol Chem 2007; 282: 34139-34147.
97. Murphy MC, Isherwood SG, Sethi S, et al. Postprandial lipid and hormone responses to meals of varying fat contents: modulatory role of lipoprotein lipase? Eur J Clin Nutr 1995; 49: 578-588.
98. Morgan LM. The metabolic role of GIP: physiology and pathology. Biochem Soc Trans 1996; 24: 585-591.
99. McGarry J. Dysregulation of fatty acid metabolism in the etiology of type2 diabetes. Diabetes 2002; 51: 7-18.
100. McIntosh CHS, Bremsak I, Lynn FC, et al. Glucose-dependent insulinotropic polypeptide stimulation of lipolysis in differentiated 3T3-L1 cells: wortmannin-sensitive inhibition by insulin. Endocrinology 1999; 140: 398-404.
101. Yip RG, Boylan MO, Kieffer TJ, et al. Functional GIP receptors are present on adipocytes. Endocrinology 1998; 139: 4004-4007.
102. Getty-Kaushik L, Song DH, Boylan MO, et al. Glucose-dependent insulinotropic polypeptide modulates adipocyte lipolysis and reesterification. Obesity (Silver Spring) 2006; 14: 1124-1131.
103. Song DH, Getty-Kaushik L, Tseng E, et al. Glucose-dependent insulinotropic polypeptide enhances adipocyte development and glucose uptake in part through Akt activation. Gastroenterology 2007; 133: 1796-1805.
104. Asmar M, Simonsen L, Madsbad S, et al. Glucose-dependent insulinotropic polypeptide may enhance fatty acid re-esterification in subcutaneous abdominal adipose tissue in lean humans. Diabetes 2010; 59: 2160-2163.
105. Duan RD, Erlanson-Albertsson C. Gastric inhibitory polypeptide stimulates pancreatic lipase and colipase synthesis in rats. Am J Physiol 1992; 262: G779-G784.
106. Rosen E, Spiegelman B. Molecular regulation of adipogenesis. Annu Rev Cell Dev Biol 2000; 16: 145-171.
107. Weaver RE, Donnelly D, Wabitsch M, et al. Functional expression of glucose-dependent insulinotropic polypeptide receptors is coupled to differentiation in a human adipocyte model. Int J Obes (Lond) 2008; 32: 1705-1711.
108. Kim S-J, Nian C, McIntosh CHS. Adipocyte expression of the glucose-dependent insulinotropic polypeptide receptor involves gene regulation by PPARgamma and histone acetylation. J Lipid Res 2011; 52: 759-770.
109. Lynn FC, Pamir N, Ng EH, et al. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes 2001; 50: 1004-1011.
110. Lynn FC, Thompson SA, Pospisilik JA, et al. A novel pathway for regulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta cells. FASEB J 2003; 17: 91-93.
111. Gupta D, Peshavaria M, Monga N, et al. Physiologic and pharmacologic modulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta-cells by peroxisome proliferator-activated receptor (PPAR)-gamma signaling: possible mechanism for the GIP resistance in type2 diabetes. Diabetes 2010; 59: 1445-1450.
112. Xu G, Kaneto H, Laybutt DR, et al. Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes. Diabetes 2007; 56: 1551-1558.
113. Rudovich N, Kaiser S, Engeli S, et al. GIP receptor mRNA expression in different fat tissue depots in postmenopausal non-diabetic women. Regul Pept 2007; 142: 138-145.
114. Kim S-J, Nian C, McIntosh CHS. GIP increases human adipocyte LPL expression through CREB and TORC2-mediated trans-activation of the LPL gene. J Lipid Res 2010; 51: 3145-3157.
115. Jansson D, Ng AC-H, Fu A, et al. Glucose controls CREB activity in islet cells via regulated phosphorylation of TORC2. Proc Natl Acad Sci USA 2008; 105: 10161-10166.
116. Fu A, Screaton RA. Using kinomics to delineate signaling pathways: control of CRTC2/TORC2 by the AMPK family. Cell Cycle 2008; 7: 3823-3828.
117. Yang R-Z, Huang Q, Xu A, et al. Comparative studies of resistin expression and phylogenomics in human and mouse. Biochem Biophys Res Commun 2003; 310: 927-935.
118. McTernan PG, Kusminski CM, Kumar S. Resistin. Curr Opin Lipidol 2006; 17: 170-175.
119. Ort T, Arjona AA, MacDougall JR, et al. Recombinant human FIZZ3/resistin stimulates lipolysis in cultured human adipocytes, mouse adipose explants, and normal mice. Endocrinology 2005; 146: 2200-2209.
120. Sethi J, Vudal-Puig A. Adipose tissue function and plasticity orchestrate nutritional adaptation. J Lipid Res 2007; 48: 1253-1262.
121. Kim J-Y, van de Wall E, Laplante M, et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 2007; 117: 2621-2637.
122. Herbach N, Goeke B, Schneider M, et al. Overexpression of a dominant negative GIP receptor in transgenic mice results in disturbed postnatal pancreatic islet and beta-cell development. Regul Pept 2005; 125: 103-117.
123. Renner S, Fehlings C, Herbach N, et al. Glucose intolerance and reduced proliferation of pancreatic beta-cells in transgenic pigs with impaired glucose-dependent insulinotropic polypeptide function. Diabetes 2010; 59: 1228-1238.